Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Mrvil, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1

Abstract

Ecotropic MuLVs induce myeloid leukemia in BXH2 mice by insertional mutagenesis of cellular proto-oncogenes or tumor suppressor genes. Disease genes can thus be identified by viral tagging as common sites of viral integration in BXH2 leukemias. Previous studies showed that a frequent common integration site in BXH2 leukemias is the Nf1 tumor suppressor gene. Unexpectedly, about half of the viral integrations at Nf1 represented a previously undiscovered defective nonecotropic virus, termed MRV. Because other common integration sites in BXH2 leukemias encoding proto-oncogenes contain ecotropic rather than MRV viruses, it has been speculated that MRV viruses may selectively target tumor suppressor genes. To determine if this were the case, 21 MRV-positive BXH2 leukemias were screened for new MRV common integration sites. One new site, Mrvi1 was identified that was disrupted by MRV in two of the leukemias. Ecotropic virus did not disrupt Mrvi1 in 205 ecotropic virus-positive leukemias, suggesting that Mrvi1 is specifically targeted by MRV. Mrvi1 encodes a novel protein with homology to Jaw1, a lymphoid restricted type II membrane protein that localizes to the endoplasmic reticulum. MRV integration occurs at the 5′ end of the gene between two differentially used promoters. Within hematopoietic cells, Mrvi1 expression is restricted to megakaryocytes and some myeloid leukemias. Like Jaw1, which is downregulated during lymphoid differentiation, Mrv1 is downregulated during monocytic differentiation of BXH2 leukemias. Taken together, these data suggest that MRV integration at Mrvi1 induces myeloid leukemia by altering the expression of a gene important for myeloid cell growth and/or differentiation. Experiments are in progress to test whether Mrvi1 is a tumor suppressor gene.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 8
Figure 7
Figure 9
Figure 10
Figure 11
Figure 12

Similar content being viewed by others

References

  • Ali IU, Lidereau R, Theillet C and Callahan R. . 1987 Science 238: 185–188.

  • Aziz DC, Hanna Z and Jolicoeur P. . 1989 Nature 338: 505–508.

  • Baffa R, Negrini M, Mandes B, Rugge M, Ranzani GN, Hirohashi T and Croce CM. . 1996 Cancer Res. 56: 268–272.

  • Bedigian HG, Taylor BA and Meier H. . 1981 J. Virol. 39: 632–640.

  • Bedigian HG, Johnson DA, Jenkins NA, Copeland NG and Evans R. . 1984 J. Virol. 51: 586–594.

  • Bedigian HG, Shepel LA and Hoppe PC. . 1993 J. Virol. 67: 6105–6109.

  • Behrens TW, Jagadeesh J, Scherle P, Kearns G, Yewdell J and Staudt LM. . 1994 J. Immunol. 153: 682–689.

  • Bepler G and Garcia-Blanco MA. . 1994 Proc. Natl. Acad. Sci. USA 91: 5513–5517.

  • Borrow J, Shearman AM, Stanton VP, Becher R, Collins T, Williams AJ, Dube I, Katz F, Kwong YL, Morris C, Ohyashiki K, Toyama K, Rowley J and Housman DE. . 1996 Nat. Genet. 12: 159–167.

  • Buchberg AM, Bedigian HG, Jenkins NA and Copeland NG. . 1990 Mol. Cell. Biol. 10: 4658–4666.

  • Chattopdahyay SK, Morse III HC, Makino M, Ruscetti SK and Hartley JW. . 1989 Proc. Natl. Acad. Sci. USA 486: 3862–3866.

  • Cho BC, Shaughnessy JD, Largaespada DL, Bedigian HG, Buchburg AM, Jenkins NA and Copeland N. . 1995 J. Virol. 69: 7138–7146.

  • Cohen GB, Ren R and Baltimore D. . 1995 Cell 80: 237–248.

  • Copeland NG and Jenkins NA. . 1991 Trends Genet. 7: 44–50.

  • Copeland NG, Jenkins NA, Gilbert DJ, Eppig JT, Maltais LJ, Miller JC, Dietrich WF, Weaver A, Lincoln SE, Steen RG, Stein LD, Nadeau JH and Lander ES. . 1993 Science 262: 57–66.

  • de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ, Oles KJ, Hultgren B, Solberg Jr, LA, Goeddel DV and Eaton DL. . 1994 Nature 369: 533–538.

  • Devereux J, Haeberli P and Smithies O. . 1984 Nucl. Acids Res. 12: 387–395.

  • Feng D-F and Doolittle RF. . 1987 J. Mol. Evol. 25: 351–360.

  • Jenkins NA, Copeland NG, Taylor BA, Bedigian HG and Lee BK. . 1982 J. Virol. 42: 379–388.

  • Jenkins NA, Copeland NG, Taylor BA and Lee BK. . 1982 J. Virol. 43: 26–36.

  • Kozak M. . 1986 Cell 44: 283–292.

  • Largaespada DA, Shaughnessy Jr JD, Jenkins NA and Copeland NG. . 1995 J. Virol. 69: 5095–5102.

  • Loh Jr WE, Scrable HJ, Livanos E, Arboleda MJ, Cavenee WK, Oshimura M and Weissman BE. . 1992 Proc. Natl. Acad. Sci. USA 89: 1755–1759.

  • Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM, Bell L, Sprecher CA, Blumberg H, Johnson R, Prunkard D, Ching AFT, Mathewes SL, Balley MC, Forstrom JW, Buddle MM, Osborn SG, Evans SJ, Sheppard PO, Presnell SR, O'Hara PJ, Hagen FS, Roth GJ and Foster DC. . 1994 Nature 369: 565–568.

  • Lupas A, Van Dyke M and Stock J. . 1991 Science 252: 1162–1164.

  • Largaespada DA, Shaughnessy JD, Jenkins NA and Copeland NG. . 1995 J. Virol. 69: 5095–5102.

  • Mayer BJ, Hamaguchi M and Hanafusa H. . 1988 Nature 332: 272–275.

  • McCormick C, Leduc Y, Matindale D, Mattison K, Esford LE, Dyer AP and Tufaro E. . 1998 Nat. Genet. 19: 158–161.

  • Methia N, Louache F, Vainchenker W and Wendling F. . 1993 Blood 82: 1395–1401.

  • McCaffery CA and DeGennaro LJ. . 1986 EMBO J. 5: 3167–3173.

  • Moskow JJ, Bullrich F, Huebner K, Daar IO and Buchberg AM. . 1995 Mol. Cell. Biol. 15: 5434–5443.

  • Mostert MC, Verkerk AJMH, van de Pol M, Heighway J, Marynen P, Rosenberg C, van Kessel AG, van Echten J, de Jong B, Oosterhuis JW and Looijenga HJ. . 1998 Oncogene 16: 2617–2627.

  • Nakai K and Kanehisa M. . 1992 Genomics 14: 897–911.

  • Nakamura T, Largaespada DA, Shaughnessy Jr JD, Jenkins NA and Copeland NG. . 1996a Nature Genet. 12: 149–153.

  • Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, Toyama K, Chen SJ, Willman CL, Chen I-M, Feinberg AP, Jenkins NA, Copeland NG and Shaughnessy Jr JD. . 1996b Nat. Gene 12: 154–158.

  • Pawson T. . 1995 Nature 373: 573–580.

  • Rogers S, Wells R and Rechsteiner M. . 1986 Science 234: 364–368.

  • Sambrook J, Fritsch EF and Maniatis T. (eds) . 1989 In: Molecular cloning, a Laboratory Manual 2nd edn. Cold Spring Harbor Laboratory Press: New York.

    Google Scholar 

  • Shannon KM, O'Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P and McCormick F. . 1994 N. Engl. J. Med. 330: 579–601.

  • Shaughnessy Jr JD, Jenkins NJ and Copeland NG. . 1997 Genomics 39: 192–197.

  • Shaw G and Kamen R. . 1986 Cell 46: 659–667.

  • Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P and Wendling F. . 1990 Cell 63: 1137–1147.

  • Suedhof TC, Czernik AJ, Kao HT, Takei K, Johnston PA, Horiuchi A, Kanazir SD, Wagner MA, Perin MS, De Camilli P and Greengard P. . 1989 Science 245: 1474–1480.

  • Tessarollo L and Parada LF. . 1995 Methods Enzymol. 254: 419–430.

  • Tetteroo PA, Massaro F, Mulder A, Schreuder-van Gelder R and von dem Borne AE. . 1984 Leuk. Res. 8: 197–206.

  • Tsao SG, Brunk CF and Pearlman RE. . 1983 Anal. Biochem. 131: 365–372.

  • Wendling F, Varlet P, Charon M and Tambourin P. . 1986 Virology 149: 242–246.

  • Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, Methia N, Breton-Gorius J, Cosman D and Vainchenker W. . 1994 Nature 369: 571–574.

Download references

Acknowledgements

This research was sponsored by the National Cancer Institute, DHHS, under contract with ABL. The contents of this publication do not necessarily reflect the views of policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. We thank J Frederic Mushinski for the plasma cell and pre B-cell mRNAs. We also thank Deborah Gilbert, Linda Cleveland and Deborah Householder for expert technical assistance. Accession no. Mouse MRVi1 U63407, U63408. Human MRVi1 AFO81249, AFO81250.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jr, J., Largaespada, D., Tian, E. et al. Mrvil, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1. Oncogene 18, 2069–2084 (1999). https://doi.org/10.1038/sj.onc.1202419

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202419

Keywords

This article is cited by

Search

Quick links